Coloplast A/ S stock (DK0060448595): Denmark medtech share under pressure ahead of valuation check

Coloplast A/S shares in Copenhagen remain under pressure after a weak spell for Danish healthcare stocks, putting the spotlight on current valuation metrics before the next earnings update.

Coloplast A/S shares on Nasdaq Copenhagen remain under pressure after a period of softer sentiment toward Danish healthcare stocks, keeping investors focused on the valuation of the medtech specialist ahead of the next earnings release, according to recent trading data for the COLO B line on the Danish market.

The stock, which is part of the OMXC25 benchmark on Nasdaq Copenhagen, most recently changed hands in the high DKK 300s to low DKK 400s region, reflecting a notable pullback from prior highs and leaving the share price below several published target levels for the Danish medical devices maker.

Coloplast A/S is headquartered in Humlebæk, Denmark, and its primary listing is on Nasdaq Copenhagen under the ticker COLO B, making developments in the Danish equity market and the broader OMX Copenhagen 20 and OMXC25 indices particularly relevant for domestic investors in the stock.

In addition to the Danish listing, Coloplast is also accessible to European retail investors through secondary trading lines in Germany, including platforms such as Tradegate and Frankfurt, where the stock is quoted in euros and tracks the underlying Danish share price converted from Danish kroner.

The share remains actively traded, with no indication from recent exchange or company disclosures of any completed take-private transaction or delisting, and it continues to feature among the healthcare names followed by Nordic and international investors focused on European medtech.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Coloplast
• Sector/industry: Healthcare - medical devices and supplies
• Headquarters/country: Humlebæk, Denmark
• Core markets: Europe, North America and selected emerging markets
• Key revenue drivers: Ostomy care, continence care, interventional urology and advanced wound and skin care products
• Home exchange/listing venue: Nasdaq Copenhagen (COLO B)
• Trading currency: DKK

Coloplast A/S: core business model

Coloplast develops and sells specialized medical devices that support people with intimate healthcare needs, with revenue mainly generated from ostomy and continence care solutions supplied to hospitals, clinics and homecare channels worldwide.

Valuation metrics and multiples for Coloplast A/S

With valuation in focus this Friday, investors are looking at how the current share price of Coloplast A/S on Nasdaq Copenhagen compares with estimates of intrinsic value and peer-group metrics, including earnings-based and cash flow-based ratios published by data providers and research platforms.

According to Morningstar data for Coloplast AS Class B as of early 2026, the stock was recently quoted at around DKK 536.00 per share while the provider's fair value estimate stood near DKK 439.00, implying that the shares were trading at a substantial premium to that particular fair value model, and highlighting that the market still assigns a high valuation multiple to the Danish healthcare group despite recent volatility.

Morningstar also characterizes the shares within the healthcare sector and medical devices industry, which typically command above-market valuation multiples when investors expect durable growth and strong cash generation, and Coloplast's premium to this fair value estimate suggests that expectations for long-term earnings and free cash flow remain significant even after periods of share price weakness.

At the index level, Coloplast B is one of the largest healthcare constituents of the OMXC25, and its valuation is often discussed in the context of other Nordic medtech and global medical technology names, where price-to-earnings and enterprise-value-to-EBITDA ratios can trade at elevated levels relative to broader European equity indices due to the perceived defensive characteristics and recurring revenue of the sector.

For investors tracking the stock from the euro area, trading in Germany on venues such as Tradegate provides an additional reference point for the valuation of Coloplast, as the euro-denominated quotes mirror the Danish price while allowing German retail investors to trade the medtech name during extended hours.

With no major new earnings release published in the immediate run-up to this valuation check, the next set of quarterly figures and any updated guidance from the company will be key in determining whether current market multiples for Coloplast A/S on Nasdaq Copenhagen remain supported by the underlying operational performance.

Conclusion

Coloplast A/S remains an actively traded Danish medtech stock on Nasdaq Copenhagen, and its current share price level keeps the debate about valuation firmly in focus for investors watching the healthcare segment.

With the shares trading at a meaningful premium to at least one published fair value estimate, market participants will likely pay close attention to the next quarterly report and any updated guidance from management to assess whether the earnings trajectory continues to justify the current multiples assigned to the business.

Until then, the stock's role within the OMXC25 and its standing among European medical device peers mean that shifts in sector sentiment and interest-rate expectations could continue to influence day-to-day trading in Coloplast A/S.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.